Supply Chain Intelligence

Alzamend Neuro, Inc. Supply Chain

ALZN supply chain intelligence for Alzamend Neuro, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ALZN ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
5Customers
2Debt Items
20Related Chains

Alzamend Neuro, Inc. Suppliers

TickerNameConfidenceEvidence
ASCENDIANT-CAPITAL-MARKETS-LLC ASCENDIANT-CAPITAL-MARKETS-LLC 92% On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ A…
LICENSOR LICENSOR 92% The November AL001 License Agreements require the Company to pay royalty payments of 3 % on net sales of products developed from the licensed technology for AL001 in those fields.
THIRD-PARTY-CONTRACTORS THIRD-PARTY-CONTRACTORS 92% We have outsourced and expect to continue to outsource the manufacturing of our products to third party contractors with special capabilities to manufacture chemical drugs and biologic drug candidate…
AULT AULT 85% We utilize resources from AULT to act as our information technology department (the "IT Department"), which functions as our Information Security Advisory Team
SUBLICENSING-TERMS-FOR-ALZN002 SUBLICENSING-TERMS-FOR-ALZN002 80% On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor
ORANY ORANY 72% These policies also outline processes to assess, identify, manage, and report cybersecurity risks and incidents. The Info-Sec Policy applies to all persons working for the Company and any third parti…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from ALZN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ALZN graph: These policies also outline proce…

Alzamend Neuro, Inc. Customers

TickerNameConfidenceEvidence
BIOPHARMACEUTICAL-COMPANIES BIOPHARMACEUTICAL-COMPANIES 90% we intend to develop AL001 and ALZN002 through successive de-risking milestones towards regulatory approval and seek marketing approval of AL001 and ALZN002 or enter into partnering transactions with…
ORANY ORANY 72% tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in significantly higher operating expenses. Expansion of our operations, to include t…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from ALZN graph: tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in…
AULT-ALLIANCE-INC AULT-ALLIANCE-INC 62% . The weighted-average period over which such stock-based compensation expense will be recognized is approximately 1.3 years. 8. WARRANTS Warrant Issuances During 2024 During the year ended April 30,…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in significantly higher operating expenses. Expansion of our operations, to include t…

Alzamend Neuro, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ALZN-DEBT-7710 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-01-31.
ALZN-DEBT-7709 Warrants outstanding: 24.35 90% xbrl warrant detail from xbrl 2025-01-31.

Alzamend Neuro, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alzamend Neuro, Inc..

Alzamend Neuro, Inc. Ownership

HolderNameConfidenceEvidence
ALZN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC GEODE CAPITAL MANAGEMENT, LLC 90% 13F overlay lists GEODE CAPITAL MANAGEMENT, LLC as top holder; 12 tracked holders.

Alzamend Neuro, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer', 'supplier']
AMZE Amaze Holdings, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
BLTE Belite Bio, Inc 50.00 2
View ALZN supply chain intel →

Explore the full interactive supply chain map for Alzamend Neuro, Inc..

Open ALZN supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map